Search

Your search keyword '"infusion-related reactions"' showing total 3 results
Start Over Descriptor "infusion-related reactions" Journal annals of hematology
3 results on '"infusion-related reactions"'

1. Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.

Author

Masamoto, Yosuke, Taoka, Kazuki, Maki, Hiroaki, and Kurokawa, Mineo

Abstract

Keywords: Follicular lymphoma; Obinutuzumab; Infusion-related reactions; Risk factors EN Follicular lymphoma Obinutuzumab Infusion-related reactions Risk factors 2795 2797 3 11/11/22 20221201 NES 221201 B Dear Editor, b The outcome of follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin's lymphoma, has been improved since the introduction of rituximab, an anti-CD20 antibody. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma. [Extracted from the article]

Published
2022
Full Text
View/download PDF

2. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.

Author

Greil, Richard, Tedeschi, Alessandra, Moreno, Carol, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Gill, Devinder, Gribben, John G., Flinn, Ian W., Wang, Zhengyuan, Cheung, Leo W. K., Nguyen, Aaron N., Zhou, Cathy, Styles, Lori, and Demirkan, Fatih

Subjects
*CYTOKINES, *CHRONIC lymphocytic leukemia, *SECRETION, *CHEMOKINES, *THERAPEUTIC use of antineoplastic agents, *RESEARCH, *INTRAVENOUS therapy, *CLINICAL trials, *PURINES, *RESEARCH methodology, *MONOCLONAL antibodies, *MEDICAL cooperation, *EVALUATION research, *PIPERIDINE, *COMPARATIVE studies, *RANDOMIZED controlled trials, *CHLORAMBUCIL, *PREANESTHETIC medication, *LONGITUDINAL method
Abstract

Anti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase 3 iLLUMINATE study of ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab in first-line chronic lymphocytic leukemia/small lymphocytic lymphoma, IRRs were substantially reduced with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab. We prospectively analyzed inflammatory cytokines to evaluate the impact of ibrutinib on circulating cytokine levels following obinutuzumab infusion. In iLLUMINATE, ibrutinib or chlorambucil was given approximately 30-120 min before the first obinutuzumab infusion. Cytokines evaluated were IFNγ, IL-6, IL-8, IL-10, IL-18, MCP-1, MIP-1α, MIP-1β, and TNFα. Changes in peak cytokine levels from baseline (immediately before obinutuzumab) to post-obinutuzumab infusion were compared between arms and between patients with versus without IRRs using Wilcoxon rank sum test. Of 228 treated patients, 95 on ibrutinib-obinutuzumab (15 with IRRs, 80 without) and 88 on chlorambucil-obinutuzumab (45 with IRRs, 43 without) with cytokine data were included. Irrespective of IRR occurrence, median increase in cytokines was lower with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab for all cytokines (P < 0.01) except MIP-1β. Across treatment arms, post-obinutuzumab median increase in all cytokines except MIP-1β was greater in patients with versus without IRRs (P < 0.001). IL-6 and IL-8 elevations were associated with IRRs in both treatment arms. Among patients with IRRs, those receiving ibrutinib-obinutuzumab had lower post-obinutuzumab increases in IL-6, IL-8, IL-10, and MCP-1 (P < 0.04) than patients receiving chlorambucil-obinutuzumab. For patients in the ibrutinib-treatment arm, we observed a reduction in both the rate of clinically apparent IRRs and the levels of IRR-related cytokines and chemokines. This observation supports an immunomodulatory mechanism of action for ibrutinib. Clinical Trial Registration: NCT02264574. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

3. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study

Author

Greil, Richard, Tedeschi, Alessandra, Moreno, Carol, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Gill, Devinder, Gribben, John G., Flinn, Ian W., Wang, Zhengyuan, Cheung, Leo W. K., Nguyen, Aaron N., Zhou, Cathy, Styles, Lori, Demirkan, Fatih, and Universitat Autònoma de Barcelona

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Chronic lymphocytic leukemia, Premedication, Infusion-related reactions, Antibodies, Monoclonal, Humanized, Gastroenterology, Proinflammatory cytokine, chemistry.chemical_compound, Piperidines, Obinutuzumab, Internal medicine, parasitic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Prospective Studies, Infusions, Intravenous, Aged, Aged, 80 and over, Hematology, Chlorambucil, business.industry, Adenine, Ibrutinib, General Medicine, Middle Aged, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Cytokine, chemistry, population characteristics, Cytokines, Cytokine secretion, Female, Original Article, business, medicine.drug
Abstract

Anti-CD20 antibody treatments, such as obinutuzumab, have been associated with infusion-related reactions (IRRs). In the phase 3 iLLUMINATE study of ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab in first-line chronic lymphocytic leukemia/small lymphocytic lymphoma, IRRs were substantially reduced with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab. We prospectively analyzed inflammatory cytokines to evaluate the impact of ibrutinib on circulating cytokine levels following obinutuzumab infusion. In iLLUMINATE, ibrutinib or chlorambucil was given approximately 30–120 min before the first obinutuzumab infusion. Cytokines evaluated were IFNγ, IL-6, IL-8, IL-10, IL-18, MCP-1, MIP-1α, MIP-1β, and TNFα. Changes in peak cytokine levels from baseline (immediately before obinutuzumab) to post-obinutuzumab infusion were compared between arms and between patients with versus without IRRs using Wilcoxon rank sum test. Of 228 treated patients, 95 on ibrutinib-obinutuzumab (15 with IRRs, 80 without) and 88 on chlorambucil-obinutuzumab (45 with IRRs, 43 without) with cytokine data were included. Irrespective of IRR occurrence, median increase in cytokines was lower with ibrutinib-obinutuzumab versus chlorambucil-obinutuzumab for all cytokines (P < 0.01) except MIP-1β. Across treatment arms, post-obinutuzumab median increase in all cytokines except MIP-1β was greater in patients with versus without IRRs (P < 0.001). IL-6 and IL-8 elevations were associated with IRRs in both treatment arms. Among patients with IRRs, those receiving ibrutinib-obinutuzumab had lower post-obinutuzumab increases in IL-6, IL-8, IL-10, and MCP-1 (P < 0.04) than patients receiving chlorambucil-obinutuzumab. For patients in the ibrutinib-treatment arm, we observed a reduction in both the rate of clinically apparent IRRs and the levels of IRR-related cytokines and chemokines. This observation supports an immunomodulatory mechanism of action for ibrutinib. Clinical Trial Registration: NCT02264574

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results